Reversal of Neuromuscular Blockade in Diabetic Patients
- Conditions
- Observation of Neuromuscular Block
- Registration Number
- NCT02057861
- Lead Sponsor
- Duzce University
- Brief Summary
In this study the investigators aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients.
- Detailed Description
Aim: In this study the investigators aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients.
Methods: Included patients were divided into 2 groups: diabetic (n=21) and non-diabetic (n=20). All patients were premedicated. After arrival in the operating room, all patients were monitorised with Datex Ohmeda S/5 Anesthesia Machine and electrocardiography (DII derivation), hemodynamic variables, respiratory rate, and inspiratory sevoflurane concentrations were recorded. Neuromuscular monitoring system was used. Anesthesia was induced with propofol 2 mg/kg and fentanyl 1 mcg/kg. After the loss of eyelid reflex the neuromuscular monitoring system automatically identified supramaximal stimulating currents and after that rocuronium 0,6 mg/kg was given. Train of four (TOF) stimulation with the supramaximal current were applied and by recording of second TOF value (TOF2) the patient was intubated. Anesthesia was maintained with 50% O2 + 50% air and sevoflurane of 1-2 % concentration. TOF stimulation was applied and recorded every 20 seconds. Intraoperatively by return T2 rocuronium 0,15 mg/kg was given. T2i time was recorded as intubation time and T2d time was recorded as clinical effect time. At the end of the operation sugammadex 2 mg/kg was given. When TOF rate reached 0,9 patients were extubated and the time was recorded.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
- The patients (diabetic and non-diabetic) between 18-65 years with risk of anesthesia I-II,
- For diabetic group patients with Diabetes mellitus Type 2 over 10 years.
- For non-diabetic group patients without any glucose metabolism disease
- myasthenia gravis, myotonic dystrophia, motor neuron diseases
- diabetic neuropathy and nephropathy
- hepatic, renal and cardiac diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reversal of diabetic patients 24 hours T2i time was recorded as intubation time and T2d time was recorded as clinical effect time. At the end of the operation sugammadex 2 mg/kg was given. When TOF rate reached 0,9 patients were extubated and the time was recorded.
- Secondary Outcome Measures
Name Time Method hemodynamic changes 24 hours Systolic, diastolic blood pressure and heart rate were recorded in the peroperative period
Trial Locations
- Locations (1)
Duzce University
🇹🇷Duzce, Turkey